These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9817188)

  • 1. Calcium antagonists and renal protection: emerging perspectives.
    Epstein M
    J Hypertens Suppl; 1998 Sep; 16(4):S17-25. PubMed ID: 9817188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The benefits of ACE inhibitors and calcium antagonists in slowing progressive renal failure: focus on fixed-dose combination antihypertensive therapy.
    Epstein M
    Ren Fail; 1996 Nov; 18(6):813-32. PubMed ID: 8948517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ACE inhibitors and calcium antagonists on progression of chronic renal disease.
    Epstein M
    Blood Press Suppl; 1995; 2():108-12. PubMed ID: 7582066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of renal disease--can it be reversed? The role of calcium channel blockers and angiotensin-converting enzyme inhibitors.
    Boner G
    Isr J Med Sci; 1996 Dec; 32(12):1217-21. PubMed ID: 9007157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium channel blockers versus angiotensin-converting enzyme inhibitors: renal effects.
    Linas S
    Am J Kidney Dis; 1990 Oct; 16(4 Suppl 1):15-9. PubMed ID: 2220796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Converting enzyme inhibitors and calcium antagonists in the long-term treatment of hypertension in chronic renal failure.
    Lenz T; August P
    Wien Klin Wochenschr; 1990 May; 102(11):315-9. PubMed ID: 2195780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the effects of ACE inhibitors and calcium channel blockers on the progression of renal failure.
    Zucchelli P; Zuccalà A; Gaggi R
    Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():46-51. PubMed ID: 8643208
    [No Abstract]   [Full Text] [Related]  

  • 11. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protection in essential hypertension: how do angiotensin-converting enzyme inhibitors compare with calcium antagonists?
    Bauer JH; Reams GP
    J Am Soc Nephrol; 1990 Nov; 1(5 Suppl 2):S80-7. PubMed ID: 16989071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal haemodynamic and protective effects of calcium antagonists in hypertension.
    Zanchi A; Brunner HR; Waeber B; Burnier M
    J Hypertens; 1995 Dec; 13(12 Pt 1):1363-75. PubMed ID: 8866898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertension as a risk factor for progression of chronic renal disease.
    Epstein M
    Blood Press Suppl; 1994; 1():23-8. PubMed ID: 8205294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When hypertension and diabetes coexist: strategies for cardiorenal protection.
    Weber MA
    Postgrad Med; 2000 Oct; 108(5 Suppl):12-8. PubMed ID: 19667536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypertension and progression of renal disease.
    Maschio G; Oldrizzi L; Marcantoni C; Rugiu C
    J Nephrol; 2000; 13(3):225-7. PubMed ID: 10928300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension with co-existing renal disease.
    Bauer JH; Reams GP
    J Hum Hypertens; 1990 Dec; 4 Suppl 5():27-34. PubMed ID: 2090835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE inhibition and renal protection.
    Ritz E
    Clin Physiol Biochem; 1992; 9(3):94-7. PubMed ID: 1302163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitor for slowing progression of diabetic and nondiabetic kidney disease.
    Myers BD; Boothroyd D; Olshen RA
    J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S66-70. PubMed ID: 11443771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.